Peptide-based immunotherapy in lupus: Where are we now?

Abstract: In autoimmune rheumatic diseases, immune hyperactivity and chronic inflammation associate with immune dysregulation and the breakdown of immune self-tolerance. A continued, unresolved imbalance between effector and regulatory immune responses further exacerbates inflammation that ultimately causes tissue and organ damage. Many treatment modalities have been developed to restore the immune tolerance and immmunoregulatory balance in autoimmune rheumatic diseases, including the use of peptide-based therapeutics or the use of nanoparticles-based nanotechnology. This review summarizes the state-of-the-art therapeutic use of peptide-based therapies in autoimmune rheumatic diseases, with a specific focus on lupus.

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
Peptide-based immunotherapy in lupus: Where are we now? ; volume:4 ; number:3 ; year:2023 ; pages:139-149 ; extent:11
Rheumatology and immunology research ; 4, Heft 3 (2023), 139-149 (gesamt 11)

Creator
P. Singh, Ram
S. Bischoff, David
S Singh, Satendra
H. Hahn, Bevra

DOI
10.2478/rir-2023-0019
URN
urn:nbn:de:101:1-2023092914041787627560
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:44 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Associated

  • P. Singh, Ram
  • S. Bischoff, David
  • S Singh, Satendra
  • H. Hahn, Bevra

Other Objects (12)